CoLucid Pharmaceuticals' P2P Acquisition

CoLucid Pharmaceuticals raised a round of funding on March 01, 2017. Investors include Eli Lilly & Co..

CoLucid Pharmaceuticals (NASDAQ: CLCD) aims to advance drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's pipeline includes lasmiditan, a trea…

Articles about CoLucid Pharmaceuticals' P2P Acquisition: